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recovery (p¼0.005). In a competing risk 2-week landmark
analysis, there were no differences grade II-IV aGVHD
incidences (61% vs 57%, p¼0.52) according to troughs.
However, patients with a lowMPA trough early post-CBT had
nearly triple the incidence of grade III-IV aGVHD (27.8% vs
9.5%, p¼0.06, Figure).
Conclusions: Higher total MPA troughs are safe and may
protect against severe aGVHD. The platelet beneﬁt could be
explained by the lower severe aGVHD incidence. Prospective
investigation of MPA troughs, and ultimately intervention
based on drug monitoring in CBT recipients is warranted.48
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In spite of intense efforts, control of graft versus host disease
(GvHD) remains incomplete and novel therapeutic ap-
proaches are required. Cdk2 has a central role in cell cycle
re-entry of mature T lymphocytes and inhibition of Cdk2 is
mandatory for induction of T cell anergy in vitro and toler-
ance in vivo. To determine the effects of Cdk2 inhibition on
GvHD, we used the B6D2F1 mouse model of allogeneic BMT
and two different Cdk2 inhibitors (Cdk2i), CYC202 and
CYC205. Lethally irradiated B6D2F1(Kd) recipients were
infused with bone marrow from C57BL/6(Kb) donors with
(BMT) or without splenocytes andwere subsequently treated
with each Cdk2i for three weeks. Treatment was adminis-
tered daily during week 1, every other day on week 2, and
twice a week on week 3 followed by assessment of GvHD
during a 70-day period. BMT recipients treated with Cdk2i
displayed a transient weight loss and subsequently regained
weight to levels comparable to controls. Treated BMT re-
cipients also displayed delayed GvHD mortality (p¼0.0054).
Treg have a central role in mediating protection from GvHD.
To examinewhether Cdk2i induced Treg, we used GFP- T cells
from Foxp3.GFP-KI mice as a source of T cells. Assessment of
peripheral blood lymphocytes, splenocytes, lymph nodes
and intestinal lymphoid cells (ILC) in treated and control
BMT recipients revealed no differences in CD4+GFP+ Treg. In
contrast, CD8+GFP+ Treg were increased in the treated group,
predominantly in ILC, which displayed a 5-fold increase of
CD8+ Treg (p¼0.05). To investigate the mechanisms via
which Cdk2i had a selective effect on CD8+ Treg, we isolated
CD4+GFP- and CD8+GFP- T cells from Foxp3.GFP-KI mice and
subjected them to in vitro Treg polarization. Cdk2i had
almost no effect on CD4+GFP+ cells but induced a 2-4 fold
increase of CD8+GFP+ cells. Culture of CD8+GFP- cells with
stable concentrations of Cdk2i and decreasing concentra-
tions of TGF-b revealed that Cdk2i induced CD8+ Treg
differentiation in the presence of TGF-b concentrations that
failed to induce CD8+ Treg cells when used alone. Expression
of FOX family genes is regulated by transcriptional and
epigenetic mechanisms. A critical epigenetic regulator of FOX
transcription factors in cancer cells is the Polycomb group
(PcG) protein, enhancer of zeste homologue 2 (EZH2), which
promotes histone H3 lysine 27 trimethylation (H3K27me3)
and induces epigenetic gene silencing. Cdk1 and Cdk2 phos-
phorylate EZH2 at Thr350 in an evolutionarily conserved
motif. Phosphorylation of Thr350 is important for EZH2
recruitment and maintenance of H3K27me3 levels at EZH2-target loci. Uponpolarizing CD8+ Tcell culture, EZH2 displayed
robust phosphorylation on Thr350, which was blocked by
Cdk2i. This event temporally coincidedwith a 44-fold increase
in Foxp3 mRNA expression compared to control T cells. These
results reveal an unexpected mechanism via which Cdk2 in-
hibitors induce CD8+ Treg and protection from GvHD.49
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Factors regulating damage and regeneration of the intestinal
epithelium after allogeneic BMT are poorly understood. We
have previously shown that IL-22 produced by recipient-
derived innate lymphoid cells (ILCs) provides a critical signal
for epithelial recovery following experimental BMT. How-
ever, intestinal IL-22 levels are reduced in GVHD due to the
elimination of radioresistant host ILCs. We therefore sought
to determine if IL-22 administration post-BMT could negate
the effect of ILC elimination and reduce GVHD pathology. We
utilized a clinically modeled LP into C57BL/6 (B6) minor
antigen mismatched model with T cell-depleted marrow and
puriﬁed T cells transplanted into lethally irradiated mice.
We found that daily administration of rIL-22 (4ug IP starting
day+7) led todecreasedGVHDpathology in recipient small and
large intestine three weeks post-BMT (p<0.001). Further
assessmentof the intestinal pathology indicated that recipients
of rIL-22 had decreased intestinal crypt apoptosis in both small
and large intestine (p<0.01)withnodifference in intestinal and
splenic lymphocytes or inﬂammatory cytokine levels.
To assess the effects of IL-22 administration on the intestinal
stem cell (ISC) compartment, we performed LP into B6 allo-
HCT using Lgr5-LacZ ISC reporter mice. Recipients treated
with rIL-22 demonstrated increased numbers of Lgr5+ ISC
three weeks post-HCT during active GVHD with no immu-
nosuppression (p<0.05). Furthermore, we found increased
ISC Ki-67 expression in Lgr5-GFP reporter mice with GVHD
after IL-22 treatment, indicating increased ISC proliferation
in response to IL-22.
In addition to Lgr5+ cells, it has been reported that BMI-1+
crypt cells may possess ISC activity after crypt damage. Crypt
cells from BMI-1-GFP reporter mice were indeed found to be
IL-22R+ at baseline (7-10% IL-22R surface expression).
However, BMI-1 mRNA expression in small intestine of mice
with GVHD was not affected by IL-22 administration,
suggesting that the effect of IL-22 administration in vivo was
not due to stimulation of BMI-1+ cells. Additionally, there
was no difference in Wnt3 or EGF expression, arguing that
improved ISC survival after IL-22 administrationwas not due
to improvement in ISC niche function. In contrast, IL-22
treatment demonstrated increased Reg3g (p<0.001) and
Reg3b (p<0.01) expression, suggesting a potential antimi-
crobial beneﬁt of IL-22 administration.
In summary, we found that IL-22 administration could
reduce intestinal pathology and improve ISC recovery in
GVHD. This appeared to be due to direct stimulation of Lgr5+
ISCs, and not due to improved support of the ISC niche. These
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represents a novel strategy to reduce gut GVHD by direct
protection of intestinal epitheliumwithout limiting immune
function post-transplant.Table 1
DBY UTY ZFY EIF1AY RPS4Y Any-HY
NMDP
(n[289)
63 (22%) 112 (39%) 22 (8%) 7 (2%) 42 (15%) 143 (49%)
Stanford
(n[90)
20 (22%) 32 (36%) 4 (4%) 1 (1%) 8 (9%) 46 (51%)
Table 2
(NMDP) cGVHD aGVHD Relapse TRM OS
HY-score HR P HR P HR P HR P HR P
0 (n[146) 1 - 1 - 1 　 1 - 1 -
1 (n[75) 1.34 0.15 1.17 0.46 1.22 0.54 0.85 0.44 0.98 0.89
2 (n[39) 1.12 0.65 1.25 0.39 0.63 0.31 0.62 0.078 0.81 0.39
3 to 4
(n[29)
1.32 0.37 1.64 0.064 1.85 0.19 1.3 0.34 1.48 0.09950
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Neddylation is crucial for the degradation of certain proteins.
However its role in regulating T cells is unknown. Neddyla-
tion is mediated by cullin-RING ligase (CRL) protein complex,
an E3 ubiquitin ligase and its critical adapter element, SAG
protein (sensitive to apoptosis gene protein). We explored
the role of SAG and thus neddylation in T cells by utilizing
two different, but complementary approaches, namely,
genetic knock-out and chemical inhibition with small
molecule. The T cell speciﬁc SAG KO animals were generated
by crossing B6 SAGﬂ/ﬂ mice with B6 LCK-Cre mice. The KO
animals were viable. The splenic and thymic analyses
showed no signiﬁcant differences in the numbers of
conventional T cells (Tcons) and Tregs between the KO and
WT animals. In vitro functional analysis of Tcons, however,
revealed that stimulation with either allogeneic splenocytes
or by a-CD3 and a-CD28 antibody, SAG-/- T cells showed
signiﬁcantly decreased proliferation (P<0.002). Phenotypic
analysis following stimulation demonstrated that SAG-/- T
cells showed reduced expression of CD69, CD44 and greater
expression of CD62L when compared to WT-T cells (P<0.04).
The KO-T cells also demonstrated reduced expression of T
effector signature cytokines, IL-17, IFN-g and IL-4. Similar
reduction in proliferation, activation marker expression and
release of cytokines was observed when the WT-T cells were
treated with small molecule inhibitor of neddylation,
MLN4924.
We next determined the in vivo relevance of SAG and
neddylation in Tcons by utilizing the MHC disparate
(B6/BALB/c) model of allogeneic BMT. The BALB/c animals
were lethally irradiated and transplanted with TCD BM from
either syngeneic or allogeneic WT-B6 animals along with
5x105 splenic T cells from either the WT B6 or SAG-/- B6
animals. The allogeneic animals that received SAG-/- T cells
demonstrated markedly reduced clinical GVHD and signiﬁ-
cantly increased survival when compared to those that
received WT-B6 T cells (P<0.001). Similar results were
observed in B6/B6D2F1 model. To further conﬁrm our
results and to determine potential translational application,
we utilized the small molecule MLN4924, once again in the
B6/BALB/c system. The recipient mice were lethally irra-
diated and received 5 doses of MLN4924 (20mg/kg, day-1 to
day +3 of BMT) along with WT-B6 T cells. Mice receiving
MLN4924 demonstrated signiﬁcantly decreased clinical
GVHD and improved survival. Our studies thus demonstrate
that SAG is a novel molecular target for regulating T cell re-
sponses and mitigating GVHD. Furthermore, the clinical
availability of the small molecule, MLN4924, suggests that
this strategy could be tested in carefully designed human
clinical trial for attenuating GVHD.51
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Background: Transplant of male recipients from female
donors (F>M HCT) is well known as a risk factor for devel-
oping chronic graft-versus-host disease (cGVHD).We have so
far suggested that B cell response against minor histocom-
patibility antigens encoded on the Y chromosome, called H-Y
antigens, develops following F>M HCT and associates with
cGVHD. Here, we hypothesize that pre-sensitization to HY-
antigen in a female donor may affect the post-HCT HY-IgG
development and clinical outcomes following F>MHCT. This
study uses our novel HY microarray to determine the prev-
alence and impact of donor HY-IgG.
Methods: Wemeasured IgG against 5 HY antigens (DBY, UTY,
ZFY, EIF1AY, &RBS4Y) in289 femaledonors (age:18-60) of high
resolution 8/8 HLA-matched HCT facilitated by the NMDP be-
tween 1990-2002 and assessed the impact of HY seropositivity
on cumulative cGVHD incidence and other clinical outcomes.
In addition, we studied 90 Stanford adult female donors
and their corresponding male recipients between 2005 and
2012 who survived without relapse for at least 3m post-HCT
and assessed the association of HY-IgG development be-
tween pre- and post-HCT. The cut-off value for seropositivity
was deﬁned as Q3 + 2xIQR, determined from plasma of 60
maledonors. HY-score was deﬁned as the cumulative num-
ber of targeted HY antigens.
Results: Prevalence of HY-IgGs in female donors is shown
in Table1. Half of female donors had at least one of 5
HY-IgG(s). Univariate analyses of NMDP cohort showed that
individual HY-IgGs in female donors were not associated
with cGVHD. Focusing on increasing HY-score, we did not
detect association with cGVHD nor other clinical outcomes
(Table 2). This absence of association was also observed in
Stanford cohort. Further, we were unable to show the
